Rubicon Research (NSE:RUBICON) Earnings Power Value (EPV): ₹3.00 (As of Mar26)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:RUBICON Rubicon Research Ltd NSE:RUBICON
18 GF Score
Price ₹1,439.60
! 3 Warning Signs
View Full Analysis

What is Rubicon Research Earnings Power Value (EPV)?

Rubicon Research NSE:RUBICON +1.45% 18 Earnings Power Value (EPV) is ₹3.00 as of Mar26. GuruFocus rates NSE:RUBICON with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

As of Mar26, Rubicon Research's earnings power value is ₹3.00. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Rubicon Research  (NSE:RUBICON) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Rubicon Research Earnings Power Value (EPV) Related Terms


Rubicon Research Earnings Power Value (EPV) Historical Data

* Premium members only.

The historical data trend for Rubicon Research's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rubicon Research Earnings Power Value (EPV) Chart

Rubicon Research Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Earnings Power Value (EPV)
0.00 0.00 0.00 0.00

Rubicon Research Quarterly Data
Mar23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Earnings Power Value (EPV) Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

NSE:RUBICON vs LLY, JNJ, ABBV: Earnings Power Value (EPV) Comparison

For the Drug Manufacturers - General subindustry, Rubicon Research's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rubicon Research Earnings Power Value (EPV) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rubicon Research's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Rubicon Research's Earnings Power Value (EPV) falls into.


NSE:RUBICON
18GF Score
Rubicon Research Ltd NSE:RUBICON
Earnings Power Value (EPV) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rubicon Research Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

What does a Earnings Power Value (EPV) of ₹3.00 mean?
Rubicon Research (NSE:RUBICON) has a Earnings Power Value (EPV) of ₹3.00 as of Mar26. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Rubicon Research and its competitors.
Is Rubicon Research's Earnings Power Value (EPV) too high?
Rubicon Research's current Earnings Power Value (EPV) is ₹3.00. Overall, Rubicon Research has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's Earnings Power Value (EPV) compare to LLY and JNJ?
Rubicon Research's Earnings Power Value (EPV) of ₹3.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Drug Manufacturers company?
A good Earnings Power Value (EPV) depends on the Drug Manufacturers industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Rubicon Research and its competitors. Rubicon Research's current Earnings Power Value (EPV) is ₹3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current Earnings Power Value (EPV) of ₹3.00. The current Earnings Power Value (EPV) is ₹3.00. Rubicon Research's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current Earnings Power Value (EPV) is ₹3.00 as of Mar26. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rubicon Research Business Description

Other Exchanges 544578:India
Address Road No. 33, MedOne House, B-75, Wagle Estate, Thane West, Thane, MH, IND, 400 604
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
18GF Score

Get the complete analysis for NSE:RUBICON

Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,439.60
Price